PMID- 17995524
OWN - NLM
STAT- MEDLINE
DCOM- 20080110
LR  - 20220311
IS  - 1320-5358 (Print)
IS  - 1320-5358 (Linking)
VI  - 12 Suppl 3
DP  - 2007 Dec
TI  - Effects of therapeutic agents on the inflammatory and fibrogenic factors in IgA 
      nephropathy.
PG  - S25-6
AB  - It is desirable in the treatment of IgA nephropathy (IgAN) to prevent the 
      downstream events after the immune response has involved the glomerulus. We and 
      others observed that IgA itself could directly activate mesangial cells to 
      produce monocyte chemotactic peptide-1 (MCP-1), interleukin-6 (IL-6) and 
      transforming growth factor-beta (TGF-beta) and this was suppressed by the 
      treatment with steroid or angiotensin receptor blocker (ARB). It was shown in 
      mesangial cells that the increased expression of TGF-beta and plasminogen 
      activator inhibitor-1 induced by angiotensin II was suppressed by the treatment 
      with ARB, calcium channel blocker (CCB), spironolactone or peroxisome 
      proliferator-activated-receptor-gamma (PPAR-gamma) agonist. It was well known in 
      the patients with IgAN that renal or intraglomerular TGF-beta1 gene expression 
      was increased. Interestingly, treatment with angiotensin-converting enzyme (ACE) 
      inhibitors induced significantly lower renal TGF-beta1 gene expression in 
      patients with IgAN. It was reported in several studies that urinary levels of 
      IL-6, IL-8, MCP-1 or TGF-beta were increased in patients with IgAN. The increase 
      was suppressed by the treatment with steroid, ARB or ACE inhibitor. More 
      effective agents are necessary to ameliorate pathogenetic abnormalities and so to 
      prevent the progression of IgAN.
FAU - Ihm, Chun-Gyoo
AU  - Ihm CG
AD  - Division of Nephrology, Kyung Hee University Medical Centre, Seoul, Korea. 
      cgihm@yahoo.co.kr
FAU - Jeong, Kyung Whan
AU  - Jeong KW
FAU - Lee, Sang Ho
AU  - Lee SH
FAU - Lee, Tae Won
AU  - Lee TW
FAU - Park, Jae Kyung
AU  - Park JK
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Nephrology (Carlton)
JT  - Nephrology (Carlton, Vic.)
JID - 9615568
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Diuretics)
RN  - 0 (Steroids)
SB  - IM
MH  - Antihypertensive Agents/*therapeutic use
MH  - Diuretics/*therapeutic use
MH  - Glomerulonephritis, IGA/*drug therapy/*immunology/pathology
MH  - Humans
MH  - Steroids/*therapeutic use
RF  - 20
EDAT- 2007/11/13 09:00
MHDA- 2008/01/11 09:00
CRDT- 2007/11/13 09:00
PHST- 2007/11/13 09:00 [pubmed]
PHST- 2008/01/11 09:00 [medline]
PHST- 2007/11/13 09:00 [entrez]
AID - NEP878 [pii]
AID - 10.1111/j.1440-1797.2007.00878.x [doi]
PST - ppublish
SO  - Nephrology (Carlton). 2007 Dec;12 Suppl 3:S25-6. doi: 
      10.1111/j.1440-1797.2007.00878.x.